CompletedNCT00666289
Familial Myeloproliferative Disorders
Studying Essential thrombocythemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Principal Investigator
- Josef Prachal, MDMyeloproliferative Disorders-Research Consortium
- Enrollment
- 17 enrolled
- Eligibility
- 7 years · All sexes
- Timeline
- 2008 – 2015
Study locations (6)
- Georgetown University, Washington D.C., District of Columbia, United States
- University of Illinois at Chicago, Chicago, Illinois, United States
- Mount Sinai School of Medicine, New York, New York, United States
- Weill Cornell, New York, New York, United States
- University of Utah, Salt Lake City, Utah, United States
- University of Florence, Florence, Italy
Collaborators
Myeloproliferative Disorders-Research Consortium · National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00666289 on ClinicalTrials.govOther trials for Essential thrombocythemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07340138Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With MyelofibrosisNovartis Pharmaceuticals
- RECRUITINGPHASE3NCT07357727A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)Novartis Pharmaceuticals
- RECRUITINGPHASE1NCT07469891A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative NeoplasmsPrelude Therapeutics
- RECRUITINGNCT06976918Registry Platform Myelofibrosis and AnemiaiOMEDICO AG
- RECRUITINGNCT07203768A ELN-Multicenter Study on Phenotypic Evolution and Clinical OutcomesFROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
- RECRUITINGPHASE2NCT06517875Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent MyelofibrosisGlaxoSmithKline
- RECRUITINGNANCT06734637Efficacy and Safety of Peginterferon in ET and PV.Zhenya Hong
- RECRUITINGPHASE1NCT06343805A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)Ajax Therapeutics, Inc.